Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 85 peer-reviewed journal articles Updated
Rheumatology

Your Diagnosis: Understanding Immune-Mediated Necrotizing Myopathy

At a Glance

Immune-mediated necrotizing myopathy (IMNM) is a rare, treatable autoimmune disease that causes severe muscle weakness because the immune system mistakenly attacks muscle fibers. Early, aggressive treatment can stop the damage and allow muscles to heal.

If you have recently been diagnosed with Immune-Mediated Necrotizing Myopathy (IMNM), you may feel like you are dealing with a disease that is as confusing as its name is long. IMNM is a rare and aggressive form of myositis (an umbrella term for diseases that cause chronic muscle inflammation) [1][2]. Unlike more common forms of myositis, IMNM is defined by necrosis—a process where the immune system mistakenly attacks muscle fibers, causing them to die [3][4].

Understanding the “Necrotizing” Difference

In many inflammatory muscle diseases, the muscle is “crowded” with inflammatory cells that cause irritation and swelling. IMNM is different because, under a microscope, a muscle biopsy shows significant muscle cell death (necrosis) but surprisingly few inflammatory cells [4][1].

Because the muscle weakness in IMNM can be severe and progressive, it is frequently misdiagnosed as muscular dystrophy [5][6]. However, there is a vital distinction: muscular dystrophy is a genetic condition caused by missing proteins, whereas IMNM is an autoimmune condition where the immune system is the active “aggressor” [7][8]. This means that while dystrophy is currently incurable, IMNM is highly treatable because the immune system can be suppressed [9][10].

Why Is IMNM So Rare?

IMNM is considered a rare disease, with an estimated incidence of only 0.6 to 5.3 cases per million people each year [11][2]. Because it is so uncommon, many general practitioners may never see a case in their entire career. This rarity often leads to delays in diagnosis or the misidentification of the disease as another type of myopathy [5][12]. To ensure the best outcomes, it is critical to assemble a specialized care team.

Three Stabilizing Facts for Your Journey

When facing a new diagnosis, it is easy to focus on the damage. Here are three facts to help ground your perspective as you begin care:

  1. Treatments Are Effective: While IMNM is aggressive, it is responsive to therapy. Doctors often use “aggressive” treatments early on—such as high-dose steroids, Intravenous Immunoglobulin (IVIG), or rituximab—to stop the immune attack and allow the muscles to begin healing [13][14][15].
  2. Your Muscles Can Regenerate: Unlike some tissues in the body, muscle has a remarkable ability to repair itself [1]. If the immune attack is halted quickly enough, “satellite cells” in your muscles can create new fibers to replace the ones that were lost [16][17].
  3. The “Window of Opportunity” Matters: Research suggests there is a critical period early in the disease where treatment is most effective at preventing permanent muscle loss (atrophy) [18][19]. Starting the right treatment plan now is the best way to protect your long-term mobility [9][10].

Subtypes and Markers

Your doctors will likely look for specific autoantibodies—proteins produced by the immune system—to further categorize your condition into one of three biological subtypes. These include:

  • Anti-SRP: Often associated with more severe weakness and sometimes involving the heart or lungs [3][20].
  • Anti-HMGCR: Frequently linked to prior use of statin medications, though it can occur in people who have never taken them [21][22].
  • Seronegative: This means no specific antibody was found, but the biopsy still confirms the pattern of muscle necrosis [23][24].

Understanding which “version” you have helps your care team choose the most effective treatment for you [3][25].

In this guide

6 chapters

01

Recognizing the Symptoms and Warning Signs of IMNM

Learn to recognize IMNM symptoms, including proximal muscle weakness, swallowing difficulties, and heart issues. Know the red flags for emergency medical care.

02

The Biology of IMNM: Three Subtypes and How They Damage Muscle

Understand the three subtypes of Immune-Mediated Necrotizing Myopathy (IMNM): anti-SRP, anti-HMGCR, and seronegative. Learn how each type damages muscle cells.

03

Diagnosis and Pathology: Understanding Your IMNM Report

Learn how to read your IMNM pathology and lab reports. Understand elevated CK levels, muscle biopsy results, MRI scans, and what they mean for your diagnosis.

04

Standard of Care: The Treatment Roadmap for IMNM

Learn the standard of care for Immune-Mediated Necrotizing Myopathy (IMNM). Understand first-line therapies, IVIG, steroids, and long-term treatment plans.

05

Survivorship and Long-Term Monitoring: Life After Diagnosis

Learn how to manage immune-mediated necrotizing myopathy (IMNM) long-term. Understand your CK baseline, heart monitoring, physical therapy, and relapse signs.

06

Building Your Care Team: Specialists and Vetting Questions

Learn how to build a care team for Immune-Mediated Necrotizing Myopathy (IMNM). Find out which specialists to see and the best questions to ask your doctors.

Common questions in this guide

What is the difference between IMNM and muscular dystrophy?
Muscular dystrophy is a genetic condition caused by missing proteins that currently has no cure. IMNM is an autoimmune disease where the immune system attacks the muscles, making it highly treatable with medications that suppress the immune system.
Can my muscles recover from immune-mediated necrotizing myopathy?
Yes, skeletal muscle has a remarkable ability to repair itself. If the immune attack is stopped early enough with aggressive treatments, specialized cells in your muscles can create new fibers to replace the damaged ones.
What does it mean if my IMNM is seronegative?
Being seronegative means that blood tests did not find the specific autoantibodies like anti-SRP or anti-HMGCR that are typically associated with the disease. However, a muscle biopsy can still confirm the diagnosis by showing the characteristic pattern of muscle damage.
Why is early treatment for IMNM so important?
There is a critical window of opportunity early in the disease where treatments are most effective at halting the immune attack. Prompt treatment helps prevent permanent muscle loss and protects your long-term mobility.
Are statin medications linked to IMNM?
Yes, prior use of statin medications for cholesterol is frequently linked to the anti-HMGCR subtype of IMNM. However, it is important to know that this subtype can still occur in people who have never taken statins.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which subtype of IMNM do I have: anti-SRP, anti-HMGCR, or seronegative?
  2. 2.Does my muscle biopsy show signs of muscle fiber regeneration, or is there significant fatty replacement (atrophy)?
  3. 3.Since IMNM can sometimes affect other organs, do I need a baseline evaluation of my heart or lungs?
  4. 4.What is my current Creatine Kinase (CK) level, and what is our target goal for that number?
  5. 5.What is our plan for 'aggressive' treatment to stop muscle necrosis as quickly as possible?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Immune-mediated necrotizing myopathy: clinical features and pathogenesis.

    Allenbach Y, Benveniste O, Stenzel W, Boyer O

    Nature reviews. Rheumatology 2020; (16(12)):689-701 doi:10.1038/s41584-020-00515-9.

    PMID: 33093664
  2. 2

    Epidemiological and genetic features of anti-3‑hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review.

    Prieto-Peña D, Ocejo-Vinyals JG, Mazariegos-Cano J, et al.

    European journal of internal medicine 2022; (101()):86-92 doi:10.1016/j.ejim.2022.04.017.

    PMID: 35487805
  3. 3

    Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy.

    Anquetil C, Boyer O, Wesner N, et al.

    Autoimmunity reviews 2019; (18(3)):223-230 doi:10.1016/j.autrev.2018.09.008.

    PMID: 30639649
  4. 4

    Statin-Induced Anti-HMGCR-Associated Myopathy.

    Basharat P, Lahouti AH, Paik JJ, et al.

    Journal of the American College of Cardiology 2016; (68(2)):234-5.

    PMID: 27386780
  5. 5

    Chronic Myopathy Associated With Anti-Signal Recognition Particle Antibodies Can Be Misdiagnosed As Facioscapulohumeral Muscular Dystrophy.

    Ikeda K, Mori-Yoshimura M, Yamamoto T, et al.

    Journal of clinical neuromuscular disease 2016; (17(4)):197-206 doi:10.1097/CND.0000000000000115.

    PMID: 27224434
  6. 6

    The Clinicopathological Distinction between Immune-Mediated Necrotizing Myopathy and Limb-Girdle Muscular Dystrophy R2: Key Points to Prevent Misdiagnosis.

    Yang M, Ji S, Xu L, et al.

    Journal of clinical medicine 2022; (11(21)) doi:10.3390/jcm11216566.

    PMID: 36362794
  7. 7

    Immune-mediated necrotizing myopathy: Unusual presentations of a treatable disease.

    Nicolau S, Milone M, Tracy JA, et al.

    Muscle & nerve 2021; (64(6)):734-739 doi:10.1002/mus.27435.

    PMID: 34617293
  8. 8

    Pediatric immune-mediated necrotizing myopathy.

    Wang CH, Liang WC

    Frontiers in neurology 2023; (14()):1123380 doi:10.3389/fneur.2023.1123380.

    PMID: 37021281
  9. 9

    Identical twins with statin-associated anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibody-positive autoimmune myopathy.

    Mali M, Pirilä L, Perander L, et al.

    Scandinavian journal of rheumatology 2024; (53(1)):81-82 doi:10.1080/03009742.2023.2289729.

    PMID: 38090763
  10. 10

    Statin-Related Necrotizing Autoimmune Myositis: More Than Myalgia.

    Scheuing WJ, Dadhania FB, Bankole AA

    Cureus 2022; (14(2)):e22654 doi:10.7759/cureus.22654.

    PMID: 35371630
  11. 11

    Increasing recognition of statin-associated anti-HMGCR antibody-positive autoimmune myopathy: a single-center retrospective study.

    Mali M, Pirilä L, Jokela M, et al.

    Clinical rheumatology 2026; (45(6)):3517-3524 doi:10.1007/s10067-026-08136-5.

    PMID: 42053859
  12. 12

    Immune-mediated necrotizing myopathy: an emerging disorder.

    Portela-Sánchez S, Catalina I, López Muñoz S, et al.

    Neurologia 2025; (40(8)):729-738 doi:10.1016/j.nrleng.2025.09.004.

    PMID: 40914455
  13. 13

    Autoimmune Myopathies: Updates on Evaluation and Treatment.

    McGrath ER, Doughty CT, Amato AA

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018; (15(4)):976-994 doi:10.1007/s13311-018-00676-2.

    PMID: 30341597
  14. 14

    Role of Intravenous Immunoglobulin in Necrotizing Autoimmune Myopathy.

    Kocoloski A, Martinez S, Moghadam-Kia S, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2022; (28(2)):e517-e520 doi:10.1097/RHU.0000000000001786.

    PMID: 34581697
  15. 15

    Evaluation of the effectiveness of using prednisolone, tacrolimus, and intravenous immunoglobulin combination therapy on immune-mediated necrotizing myopathy-A non-randomized, observational research.

    Liu M, Liu J, Li K, et al.

    International journal of rheumatic diseases 2024; (27(3)):e15124 doi:10.1111/1756-185X.15124.

    PMID: 38514893
  16. 16

    Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy.

    Lim J, Rietveld A, De Bleecker JL, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2019; (6(1)):e513 doi:10.1212/NXI.0000000000000513.

    PMID: 30345336
  17. 17

    Immune-Mediated Necrotizing Myopathy: A Systematic Review of Antibody-Specific Mechanisms and Treatment Outcomes.

    Vaezi Z, Amini A

    Cureus 2025; (17(11)):e97933 doi:10.7759/cureus.97933.

    PMID: 41458822
  18. 18

    Preclinical biomarkers of prion infection and neurodegeneration.

    Mok TH, Mead S

    Current opinion in neurobiology 2020; (61()):82-88 doi:10.1016/j.conb.2020.01.009.

    PMID: 32109717
  19. 19

    Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.

    Herbort CP, Abu El Asrar AM, Yamamoto JH, et al.

    International ophthalmology 2017; (37(6)):1383-1395 doi:10.1007/s10792-016-0395-0.

    PMID: 27844182
  20. 20

    Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.

    Watanabe Y, Uruha A, Suzuki S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2016; (87(10)):1038-44 doi:10.1136/jnnp-2016-313166.

    PMID: 27147697
  21. 21

    Anti-HMGCR antibodies and asymptomatic hyperCKemia. A case report.

    Torri F, Ali G, Chico L, et al.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2021; (40(2)):105-108 doi:10.36185/2532-1900-050.

    PMID: 34355128
  22. 22

    Statin-naïve anti-HMGCR antibody-mediated necrotizing myopathy in China.

    Jiao Y, Cai S, Lin J, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2018; (57()):13-19 doi:10.1016/j.jocn.2018.08.010.

    PMID: 30205933
  23. 23

    The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China.

    Ma X, Xu L, Ji S, et al.

    Frontiers in neurology 2021; (12()):670784 doi:10.3389/fneur.2021.670784.

    PMID: 34290662
  24. 24

    Immune-Mediated Necrotizing Myopathy.

    Pinal-Fernandez I, Casal-Dominguez M, Mammen AL

    Current rheumatology reports 2018; (20(4)):21 doi:10.1007/s11926-018-0732-6.

    PMID: 29582188
  25. 25

    Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.

    Pinal-Fernandez I, Parks C, Werner JL, et al.

    Arthritis care & research 2017; (69(2)):263-270 doi:10.1002/acr.22920.

    PMID: 27111848

This page provides an educational overview of immune-mediated necrotizing myopathy. It does not replace professional medical advice; always consult your specialist regarding your specific subtype and treatment plan.

Get notified when new evidence is published on Immune-mediated necrotizing myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.